Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Recruiting 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 66Pancreatic Neoplasms 35Neuroblastoma 21Neoplasm Metastasis 21Neoplasms 16Colonic Neoplasms 15Stomach Neoplasms 14Rectal Neoplasms 13Esophageal Squamous Cell Carcinoma 9Sarcoma, Ewing 8Rhabdomyosarcoma 8Small Cell Lung Carcinoma 7Sarcoma 7Ovarian Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Esophageal Neoplasms 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Medulloblastoma 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Osteosarcoma 3Locally Advanced Rectal Cancer 3Glioma 3Glioblastoma 3Gastrointestinal Neoplasms 3

Interventions

Fluorouracil 16Oxaliplatin 14Nivolumab 14Leucovorin 13pembrolizumab 9Paclitaxel 9Capecitabine 9Radiotherapy 6Radiation 6durvalumab 5Taxes 5Irinotecan 5Cisplatin 5Trastuzumab 4Specimen Handling 4Drug Therapy 4Carboplatin 4tremelimumab 3dehydroftorafur 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Endoscopy 3Docetaxel 3Biopsy 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2tislelizumab 2futibatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Irinotecan × 1 year × Clear all
NCT05677490 2026-05-08

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
382 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06846346 2026-04-28

GRACIE

UNICANCER

Phase 2 Recruiting
88 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT02366819 2026-03-30

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

University of Chicago

Phase 4 Suspended
36 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06356311 2026-02-27

TroFuse-015

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡